Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Maybe not. Let's look at how it might perform in the next half-decade. Merck's most important product is Keytruda, a cancer drug that has won approval to treat scores of indications. Keytruda has ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

While healthcare plan providers and pharmaceutical firms often capture consumer attention ... is a standout product with ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

and the percentage of total revenues each product accounts for. We might conclude that Merck actually delivered a fairly impressive performance in Q2, with key divisions such as Oncology ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc ...